TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Histologically confirmed, primary, previously untreated, resectable squamous cell carcinoma of the oral cavity considered clinically and radiologically as intermediate or high risk, classified II ( with large (≥ 3 cm and ≤ 4cm) cT2cN0cM0 tumors or any cT2cN0cM0 tumor invading neighboring structures) III or IVa according to the American Joint Committee on Cancer~* Adequate liver and renal function~Exclusion criteria:~* Other malignancy~* Abnormal cardiac status~* Autoimmune disease~* Serious concurrent uncontrolled medical disorder~* Systemic treatment with corticosteroids or other immunosuppressive agents within 30 days prior to IPH2201 first administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- single arm (Type: EXPERIMENTAL): IPH2201 followed by standard surgery and standard postsurgical adjuvant therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1B Study of KSP/QRH Dimer for Detection of Neoplasia in the Esophagus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Has known or suspected Barrett's esophagus~* Scheduled for a clinically-indicated, upper endoscopy~* Subject is medically cleared for the procedure (e.g. washout for anticoagulants, co-morbidities)~* Age 18 to 100 years~* Willing and able to sign informed consent~Exclusion Criteria:~* Subjects with known allergy or negative reaction to the near infrared fluorophore IRDye800CW, or derivatives~* Subjects on active chemotherapy or radiation treatment~* Pregnant or trying to conceive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Esophagus sprayed with KSP/QRH dimer (Type: EXPERIMENTAL): Area of interest in subject's esophagus sprayed with KSP/QRH dimer and imaged with the SFE probe

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prior histologic confirmation of non-small cell lung cancer (NSCLC).~* Optional: NSCLC histologic confirmation of metastasis of NSCLC.~* Presence of unidimensionally measurable disease in the brain.~* No previous or current malignancies at other sites with the exception of adequately treated in situ carcinoma of the cervix or basal and squamous carcinoma of the skin.~* Age: \>18 years.~* Subjects must not have systemic disease that in the opinion of the investigator is in immediate need of chemotherapy~* Karnofsky Performance status \>=70%.~* Absolute neutrophil count (ANC) \>1,500/mm\^3, platelets \>100,000/mm\^3, hemoglobin \>8 g/dL.~* Serum creatinine and bilirubin \<1.5 times upper normal limit of testing laboratory.~* Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) \<3 times upper limit of testing laboratory.~* Palliative radiation therapy to thorax and bone or other organs (except brain) is acceptable.~* Prior neurosurgery \>2 weeks from initiating treatment with temozolomide.~* Cortisone medication stable or decreasing within 2 weeks prior to initiating treatment with temozolomide.~* Patient is not pregnant or nursing and is advised and willing to use an effective method of contraception.~* Written informed consent.~Exclusion Criteria:~* Chemotherapy or biologic therapy within four weeks prior to initiating therapy with temozolomide.~* Prior radiation therapy for brain \<4 weeks from initiating therapy with temozolomide.~* Surgery within two weeks prior to temozolomide administration.~* Recursive Partitioning Analysis (RPA) class III~* Patients with a single brain metastasis amenable to radiosurgery of resection~* Known Human Immunodeficiency Virus (HIV) disease.~* Acute infection requiring intravenous antibiotics.~* Any reason making compliance to the protocol improbable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy with temozolomide and radiotherapy (Type: EXPERIMENTAL): None
- Radiotherapy alone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Outcomes in Chronic Low Pain Back Utilizing Activity Trackers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is at least 18 years age and younger than 75 years of age~* Subjects evaluated and found to have low back lasting longer than 3 months~Exclusion Criteria:~The subject suffers from any of the following:~* Foot drop~* Recent diagnosis of malignancy~* Recent infection~* Saddle anesthesia~* Urinary or bowel incontinence~* Progressive neuromotor or sensory loss~  * The subject is unable to complete the assessment tools~ * The subject is pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ACTIVITY TRACKER (Type: EXPERIMENTAL): Subjects in Cohort A will receive standard of care treatments in addition to a Fitbit Flex 2 activity tracker for six weeks and recommendation for daily step counts at initial visit. Cohort A will then meet with researchers via telehealth at 2 weeks and 4 weeks with researchers to review step counts and reaffirm targets. Subjects in Cohorts A will be reassessed in person at the conclusion of the six week period.
- Control (Type: PLACEBO_COMPARATOR): Subjects in Cohort B will receive standard of care treatments in addition to a Fitbit Flex 2 activity tracker for six weeks and recommendation for daily step counts at initial visit. Subjects in Cohorts B will be reassessed in person at the conclusion of the six week period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Placebo for Functional Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Functional Dyspepsia~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- open-label placebo (Type: EXPERIMENTAL): open-label placebo
- treatment as usual (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Do Oral Steroid Dose Packs Predict How Well Epidural Steroid Injections Will Work?

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years and older~* Diagnosed by participating physicians during the study enrollment period as having intervertebral disk herniation and persistent symptoms with or without some nonoperative treatment for at least 4 weeks~* Radicular pain (below the knee for lower lumbar herniations, into the anterior thigh for upper lumbar herniations)~* Evidence of nerve-root irritation with a positive nerve-root tension sign (straight leg raise-positive between 30° and 70°) or a corresponding neurologic deficit (asymmetrical depressed reflex, decreased sensation in a dermatomal distribution)~* Undergone either MRI or CT scan showing disc herniation (protrusion, extrusion, or sequestered fragment) at a level and side corresponding to the clinical symptoms~* Patients with multiple herniations can be included if only one of the herniations is considered symptomatic~* Preenrollment nonprocedural care can include: education/counseling, physical therapy, chiropractic therapy, anti-inflammatory medications, opioid analgesics, adjuvant analgesics such as anticonvulsants and antidepressants~Exclusion Criteria:~* Prior lumbar surgery~* Cauda equina syndrome~* Vertebral fractures~* Spine infection or tumor~* Severe motor deficit~* Inflammatory spondyloarthropathy~* Pregnancy~* Cardiac or pulmonary comorbid conditions contraindicating interventional procedures~* Diabetes~* Inability/unwillingness to have spinal injections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the GTX™ 5126 DES Coronary Stent System in the Treatment of Patients With a Lesion in the Coronary Artery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Patient has discrete de novo lesion of a coronary artery with symptomatic ischemic heart disease~* Planned treatment of one lesion with a single stent~* Denovo type A, B1 lesions with a Reference diameter between 3.0 and 3.5mm and a lesion length between 5 and 16mm~Key Exclusion Criteria:~* Diabetic (HbA1C \>6.0)~* Platelet count \< 100000 cells/mm3 or \> 700000 cells/mm3; WBC \< 3000 cells/mm3; or a hemoglobin \< 10 g/dl~* Renal dysfunction with creatinine \> 2.0 mg/dl~* Patient has a known pre-dilatation ejection fraction (EF) less than forty five (\<45%)~* Myocardial infarction (MI) less than 3 months prior to intervention~* Patient has type B2, C lesion~* Reference artery diameter \<3.0 or \>3.6 mm~* Target lesion length \< 5mm and \>16 mm~* Other stenosis \>50% in target vessel~* Known hypersensitivity or contraindication to aspirin, clopidogrel, ticlopidine, or cobalt chromium, or a sensitivity to contrast agent that, in the opinion of the investigator, cannot be adequately premedicated.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: NOA-12: BIBF1120 and R-RT in Glioblastoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients with a recurrence / progression of glioblastoma either not being eligible for tumour resection or having macroscopic residual tumour after resection of the recurrence~* Diagnosis of glioblastoma must be proven histologically and progress must be documented by MRI. MRI images must not be older than 2 weeks before first dosing/start of RT~* Not more than two prior therapy regimens including one or two resections, one or two chemotherapies (one temozolomide containing concomitant to radiotherapy) and one radiotherapy (RT) for the brain tumour~* Previous irradiation therapy of the primary tumour with a maximal dose of 60 Gy; at least 8 months since the end of preirradiation~* Candidate for reirradiation with recurrent tumour visible on MRIT1 (Gd) and with the largest diameter measuring 1 cm to 5 cm~* Informed consent~* Age ≥ 18 years, smoking or non-smoking, of any ethnic origin~* Karnofsky performance index (KPI) ≥ 60%~* Neutrophile counts \> 1500/μl / Platelet counts \> 80.000/μl /Haemoglobin \> 10 g/dl / Serum creatinine \< 1.5-fold upper normal range / Bilirubin, AST or ALT \< 2,5-fold upper normal range unless attributed to anticonvulsants / Alkaline phosphatase \< 2,5-fold upper normal range~* Adequate contraception~* If on steroids, stable or decreasing treatment with steroids within 5 days before treatment start~Exclusion Criteria:~* More than one RT of brain, prior first radiotherapy with more than 60 Gy~* Cumulative total dose on the optical chiasm \>54 Gy for 2 Gy/fraction, α/β=2~* Prior treatment with bevacizumab, iodine seeds and/or brachytherapy~* Unable to undergo MRI~* Past medical history of diseases with poor prognosis according to the judgement of the Investigator, e.g. severe coronary heart disease, severe diabetes, immune deficiency, residual deficits after stroke, severe mental retardation~* HIV or hepatitis infection~* Pregnancy or breast feeding~* Treatment within any other clinical trial parallel to the treatment phase of the current study or within 30 days before inclusion~* Known coronary artery disease, significant cardiac arrhythmias or severe congestive heart failure (NYHA class III - IV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIBF 1120 + reirradiation (Type: EXPERIMENTAL): 2 x minimal tolerated dose BIBF 1120 per day in combination with radiotherapy (2 Gy / fraction; 36 Gy in total)
- reirradiation alone (Type: ACTIVE_COMPARATOR): radiotherapy (2 Gy / fraction; 36 Gy in total)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Phone Call About Financial Reimbursement Program on Access to Cancer Clinical Trials

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~COHORT A:~* Eligible patients to be randomized for the iMPACT study must:~  1. Carry a diagnosis of cancer~ 2. Patient is considered potentially eligible for a cancer therapeutic clinical trial (TCT) and is being offered an opportunity to sign an informed consent document for the cancer TCT~* Eligible patients to receive FRP (these documents will be requested by Lazarex Foundation, however research coordinator at site can help patient collect documents):~  1. Have a household income =\< 700% of the 2018 Health and Human Services (HHS) Poverty Guidelines~ 2. Willing to provide proof of household income. Acceptable proof of income documents are: first two pages of signed copy of income tax return, or if a return is not filed, a copy of the most recent pay stub, unemployment check, Supplemental Security Income (SSI), Social Security Disability (SSD), or public assistance benefit notification. If a patient is not employed, they must submit a signed letter stating their current financial situation

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A : Usual Care (FRP Only) (Type: ACTIVE_COMPARATOR): Patients or parents/legal guardians of patients receive FRP brochure at the time of iMPACT consent.
- Cohort A: Usual Care + Intervention (FRP + Follow-up) (Type: EXPERIMENTAL): Patients or parents/legal guardians of patients receive FRP brochure at the time of iMPACT consent and a follow-up phone call on day 3 after iMPACT consent.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Multicentre Trial to Compare Two Articulating Bearing Surfaces as Used in Cementless Primary Hip Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary total hip replacement~* Patient with degenerative joint disease (inflammatory or non-inflammatory) or any of the composite diagnoses of osteoarthritis,avascular necrosis, legg perthes, rheumatoid arthritis, diastrophic variant, fracture of the pelvis, fused hip, slipped capital epiphysis, subcapital fractures, traumatic arthritis~* Patients preoperative Harris hip score \< 80 points~* Patients with limited co-morbidity - ASA I - III~* Patients with normal urea and electrolyte levels and creatinine levels~* Patients must be able to understand instructions and be willing to return for follow-up~* Patients willing to provide blood and urine samples for metal ion analysis at follow-up~Exclusion Criteria:~* Patient preoperative Harris hip score \> 80 points~* Pre-existing metal implants~* Patients with significant co-morbidity - ASSA IV - V~* Dementia and inability to understand and follow instructions~* Neurological conditions affecting movement~* Women younger than 45 years old~* Presence of symptomatic arthritis in other lower limb joints~* Patients requiring smaller than 38mm and larger than 60mm diameter femoral heads~* Patients taking NSAIDs and / all drugs that will affect bone metabolism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Metal on ceramic articulation (Type: EXPERIMENTAL): The arm consists of patients with Ceramic femoral heads articulating with metal acetabular cups
- Metal-on-metal (Type: ACTIVE_COMPARATOR): The arm consists of patients with Metal femoral heads articulating with metal acetabular cups

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patient's age between 18 and 75 years.~2. Presence of microscopic diagnosis of pancreatic cancer.~3. The disease is Locally advanced deemed by the surgeon to be unresectable, or metastatic disease.~4. Karnofsky Performance status \>50%.~5. Prior radiotherapy for local diseases is allowed provided disease progression had been documented, and treatment completed at least 4 weeks before random assignment~6. Prior chemotherapy is not permitted, except for fluorouracil given concurrently as a radiosensitizer.~7. Patients must have normal organ function evidenced by~   * Cr \<1.5 ULN~  * ANC \>1000~  * platelets\> 100,000~  * total bilirubin \<1.5ULN.~8. Pain should be controlled for at least two weeks without an increase in the narcotic consumption.~9. Biliary obstruction should be controlled for at least two weeks evident by stable or improving liver function tests especially total bilirubin.~10. Patient has signed a Patient Informed Consent Form.~11. For all females of childbearing potential, a negative pregnancy test must be obtained within 72 hours before starting therapy.~Exclusion Criteria:~1. Contraindication to chemotherapy.~2. Evidence of uncontrolled CNS disease (patients with controlled CNS disease for 4 weeks using the same imaging method and for whom are off steroid will be eligible)~3. Uncontrolled Nausea and Vomiting~4. Diagnosis of other malignancy in the last 5 years excluding non-melanoma skin cancer and in -situ cervical cancer.~5. Subjects unlikely to comply with protocol, e.g. uncooperative attitude, inability to return for follow- up visits and unlikelihood of completing the study.~6. Any known history of hypersensitivity to the study drugs.~7. Pregnant or lactating women.~8. Participation in a clinical trial with any investigational drug used with curative intent and within 30 days prior to study entry~9. Peripheral sensitive neuropathy with functional impairment prior to study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patient (male or female) ≥12 years of age~* ECOG (Eastern Cooperative Oncology Group) performance status ≤1~* Must have progressed following standard therapy, or for whom, in the opinion of the Investigator, no effective standard therapy exists, is tolerated or appropriate.~* Patients must be willing and able to undergo study required biopsies.~* Presence of at least one measurable lesion according to RECIST v1.1.~* Documented MAPK pathway alteration~Exclusion Criteria:~* Prior treatment with ERK inhibitors.~* History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO.~* Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.~* Patients receiving proton pump inhibitors (PPI) which cannot be discontinued 3 days prior to the start study treatment and for the duration of the study.~* Patients with malignant disease other than that being treated in the study.~* Clinically significant cardiac disease.~Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Escalation (Type: EXPERIMENTAL): None
- Expansion Group 1 (Type: EXPERIMENTAL): None
- Expansion Group 2 (Type: EXPERIMENTAL): None
- Expansion Group 3 (Type: EXPERIMENTAL): None
- Expansion Group 4 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy